• Innovent Biologics announced Oct. 23, 2026, that arcotatug tavatecan met both primary survival endpoints in the Phase 3 G-HOPE-001 gastric cancer trial.
• The drug significantly improved overall survival and delayed disease progression versus physician-selected treatments in previously treated patients with CLDN18.2-positive advanced gastric cancer.
• Results were presented at the 2026 European Society for Medical Oncology Congress; additional analyses will be shared at a future congress or published.
• Treatment-related severe adverse events were less frequent than with comparator therapies, with low rates of severe gastrointestinal events.
• Arcotatug tavatecan became the first CLDN18.2-targeted antibody-drug conjugate globally to have a new drug application accepted for regulatory review.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610230609PR_NEWS_USPR_____CN79693) on October 23, 2026, and is solely responsible for the information contained therein.